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Moderate severity asthma occurs in approximately 10 to 15% of patients with chronic reversible airway obstruction and is de-
fined by more than four daytime symptoms per week, more than four night time symptoms per month and peak expiratory flow 
rates of between 60 and 80% of predicted values. Currently recommended first line chronic maintenance treatment for children 
and adults for moderate severity asthma is the use of combination therapy of inhaled corticosteroids and long acting beta-2 
agonists. Other agents such as leukotriene receptor antagonist, theophyllines and soluble TNF alpha-receptor blockers could 
be considered in special circumstances when adequate control is not obtained.
INTRODUCTION
Asthma is a chronic disease with air-
flow limitation due to inflammation and 
smooth muscle bronchial constriction. 
According to the latest international 
guidelines, a major paradigm shift has 
occurred in the care of patients with 
asthma. The value of the classifications 
of patients according to their severity of 
disease for chronic maintenance man-
agement as intermittent or persistent 
(mild, moderate or severe) disease is 
being questioned. Recently asthma has 
been classified either as controlled or 
uncontrolled with treatment adjusted 
accordingly. For assessment of control, 
GINA utilises characteristics such as 
symptoms, usage of medication and 
variation of peak flow readings only, 
and these have been employed in the 
recent GOAL study to define well or total 
controlled asthma.  These parameters 
alone do not give the complete picture 
of asthma control as other markers of 
allergic inflammation such as exhaled 
nitric oxide, eosinophic cationic pro-
tein, etc. and non- allergic inflamma-
tions, e.g. cytokines such as TNF alpha 
(neutrophilic inflammation) were not 
considered. In addition, methacholine 
challenge testing (degree of bronchial 
reactivity), lung biopsy (pathological 
severity of disease) and quality of life 
issues are not included in the evaluation 
of asthma control. With the addition of 
these markers and genetic studies of 
asthmatics, it may be possible within the 
next decade to accurately determine 
the specific type of asthma, the most 
appropriate therapeutic option and what 
adjustments we need to make in the 
medications to ensure optimal control. 
This would enhance the management 
model of stepping up or down therapy 
according to predefined targets of con-
trol rather than classifying patients into 
different severity categories.
IMPACT OF POORLY CONTROLLED 
ASTHMA
Uncontrolled childhood asthma has a 
significantly impact on quality of life is-
sues related to parents and children. It 
results in school absenteeism, multiple 
visits to doctors and hospital admis-
sions for the asthmatic and sleepless 
nights and work absenteeism for the 
parent/caregiver. Improved therapy that 
provides optimal control is available to 
provide a better quality of life for these 
family units
MODERATE SEVERE ASTHMA: CLAS-
SIFICATION AND PREVALENCE
The current South African Thoracic 
Society and South African Childhood 
Asthma Working Group define moder-
ate severe asthma in adults and children 
as more than four daytime symptoms 
per week, more than four night time 
symptoms per month and peak expira-
tory flow rates of between 60 and 80% of 
predicted values. Utilising this definition 
it is expected that approximately only 
10 to 15% of asthma sufferers would 
be categorised as moderate severity 




As asthma has predominantly been 
recognised as a disease of eosinophilic 
and IgE mediated inflammation, the cor-
nerstone of management is the use of 
corticosteroids. The medications used in 
the management of adults and children 
of any age are similar with variations just 
in the drug doses required. The inhaled 
route is the preferred method of admin-
istration as the medication is required in 
the airways and lungs and utilisation in 
this form allows for a lower drug dosage 
with a better safety profile. The recom-
mended drug dosage for adults with 
moderate severity disease is 500mg to 
1000mg of beclomethasone dipropio-
nate equivalent per day (medium dose) 
while half this dose is used in children. 
The major concern with the use of cor-
ticosteroids is the safety profile of these 
medications at high doses (> 1500 ug of 
BDP equivalent) of the inhaled medica-
tion or with recurrent or persistent use of 
the oral form of the drug.
 
Long acting Beta-2 agonist (LABA) 
and ICS
Over the last decade several large stud-
ies in adults have confirmed the benefit 
of commit ant use of inhaled long acting 
beta-2 agonist (LABA) with inhaled cor-
ticosteroids. The pivotal Greening study 
demonstrated that addition of a LABA to 
low dose inhaled corticosteroid (100 to 
500mg BDP equivalent) had the same 
effect as using double the prescribed 
dose of steroids (500 to 1000mg BDP 
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equivalent corticosteroid per day). 
LABA potentiates the effect of cortico-
steroids by priming the glucocorticoid 
receptor and thus increasing activity 
while the corticosteriod induced replica-
tion of proteins important in producing 
beta-2 adrenoceptor and decreasing 
desensitisation of the beta-2 receptors. 
This self-perpetuating loop between 
LABA and corticosteroids allows for 
a lower dose of corticosteroids to be 
used to obtain control and is known 
as a steroid sparing effect. This effect 
is accentuated at a certain threshold 
value (flat dose response curve) for cor-
ticosteroids where the benefit of adding 
LABA is believed better than doubling 
the dose of corticosteroids.
Similar data has been shown in 6 double 
blind placebo controlled trials in child-
hood and adolescences. The addition of 
either LABA or placebo to corticosteroid 
therapy, statistical significant benefit in 
terms of bronchodilatation (benefit in 
symptom free days, FEV1 and morning 
PEF) was seen with the LABA over the 
placebo; although the effects were not 
as marked as in adults. The comparison 
with doubling dose of steroids versus 
adding a LABA was assessed in two 
studies in children benefits in terms of 
symptom score, exacerbations rates, 
PEF and FEV1 measurements and re-
duction in BHR were seen in the groups 
on LABA with inhaled corticosteroids. 
In summary LABA given in conjunction 
with appropriate inflammatory treatment 
particularly inhaled corticosteroids as 
a regular add-on treatment reduces 
the rate of exacerbations, decreases 
bronchial hyperactivity and is more 
advantageous than using either medi-
cation alone. Sekhsaria and colleagues 
found that a combination of fluticasone 
and salmeterol significantly reduce the 
number of emergency room visits and 
hospitalisations (p<0.001) in children 
with mean age of 35 months (range 5-60 
months) with mild to moderate disease. 
The South African Childhood Asthma 
working group guidelines on chronic 
maintenance therapy for asthma recom-
mends the use of combination therapy 
of a medium dose of corticosteroids and 
either LABA in children with moderate 
severity disease who are still symptom-
atic (step3). 
Benefit of ICS and LABA adminis-
trated through a single device 
Evidence that the administration of com-
bination therapy of ICS and LABA was 
beneficial had led major pharmaceutical 
companies to produce these medica-
tions in a single device. Surprisingly, 
this intervention became a therapeutic 
advancement as studies of the combi-
nation medication in the single device 
were shown to be superior to providing 
each medication separately. Recently, in 
the GOAL and START studies, combina-
tion therapy is a single device was found 
to improve control of asthma in different 
severity of chronic asthma, raising the 
question of the usefulness of the clini-
cal classification (mild, moderate and 
severe persistent disease). Based on 
these findings it would be prudent to 
classify asthma as controlled or uncon-
trolled with adjustment of medication 
accordingly. As a consequence of the 
bronchodilator and anti-inflammatory 
properties of the combination therapy 
and the added benefit of rapid acting 
long acting beta- 2 agonist formoterol, 
studies have suggested that the single 
device combination of budesonide and 
formoterol could be used as a control-
ler (chronic maintenance) and reliever 
during an acute exacerbation. Although 
this seems an interesting prospect, 
it requires careful consideration as 
long-term airway inflammation may be 
masked by the repeated use of the 
LABA bronchodilator.  This may result 
in underestimation of degree of uncon-
trolled asthmatic inflammation requiring 
increased dose of corticosteroids and 
could lead to unexpected asthma re-
lated deaths.
Other considerations as add-on medi-
cation to ICS for moderate severity 
asthma
Leukotriene receptor antagonists 
(LTRA)
These agents play a role in airway re-
modeling and decreasing eosinophil 
traffic and are considered mainly as 
anti-inflammatory medications. Malm-
estrom K et al has shown that inhaled 
corticosteroids are a more potent anti-
inflammatory than leukotriene receptor 
antagonist. Glucocorticoids however, 
have little effect on the cysteinyl leukot-
riene pathway. The addition of a LTRA 
or doubling the dose of inhaled cortico-
steroids in the Compact study showed 
no difference in the outcome while the 
comparison of the addition of either 
LTRA or LABA in the cross over design 
in the Impact study showed equivalence 
in preservation of lung function in adult 
asthmatics with moderate severe dis-
ease. This suggests that leukotrienes do 
have a role to play in asthmatics with un-
controlled asthma where the threshold 
of risk – benefit ratio for cotricosteroids 
are reached. Furthermore it has a role 
to play in adults and children with spe-
cific phenotype asthma i.e. aspirin in-
duced disease or viral induced wheeze 
(asthma). 
Low dose theophyllines
The benefit of adding these agents to 
ICS in moderate severe disease has 
been demonstrated in studies by Evans 
et al. In a Cochran review of 6 studies 
evaluating the role of theophyllines, Wil-
son AJ et al showed that LABA was more 
effective than theophyllines although the 
latter being are much cheaper. 
Newer agents: soluble TNF alpha re-
ceptor fusion protein
Given that TNF alpha is an important 
cytokine is asthmatic neutrophilic in-
flammation, the use soluble TNF alpha-
receptor fusion protein such etanercept 
has recently shown benefit. In a placebo 
controlled trial of refractory asthmatics 
on corticosteroids, etanercept given 
twice weekly for 10 weeks showed im-
provement in asthma symptom scores, 
lung function, bronchial hyper-respon-
siveness and quality of life scores. No 
improvement was seen with allergic 
inflammation and the long-term safety of 
this medication still need to determined.
ADVERSE EFFECTS
Concerns over ICS
The safety of corticosteroids is dose 
related. High cumulative doses of ste-
roids are associated with the more seri-
ous side effects of osteoporosis, blood 
abnormalities, cataracts, suppression 
of the hypothalamic pituitary axis. Low 
and medium doses of inhaled cortico-
steroids are safe and have minor side 
effects such as oral candidiasis and 
delayed growth (height). These can be 
limited by rinsing the contents of the 
mouth after inhalation of the corticoste-
roid. Suppression of the adrenal-cortical 
axis has been demonstrated with use of 
high doses and appropriate tests should 
be undertaken at regular intervals (6 
monthly) in patients with high dose of 
steroids. Oral steroids carry a much 
higher risk for inducing adverse effects 
than inhaled steroids. In a recent study 
of children between 5 and 60 months of 
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age, a non-significant reduction of only 
3.4% in height of children on combina-
tion therapy was noted with suppression 
more marked in males than females. 
Asthma itself has been noted to reduce 
onset of puberty and slow preadolescent 
growth velocity. The authors conclude 
that concerns over height should be 
viewed in relation to benefits of effective 
disease control from steroids. Moreover, 
suppression is temporary and child-
hood asthmatics ultimately reach their 
predicted adult height.
Concerns over LABA 
Use as monotherapy
LABA have no effect on exhaled Nitric 
Oxide, eosinophil levels and on bron-
chial hyper reactivity (BHR) and are 
not anti-inflammatory and should not 
be used as monotherapy in persistent 
asthma. 
Effect on bronchoprotection
LABA has a small effect on bronchial 
protection against exercise-induced 
bronchoconstriction or other irritants in 
children with regular use. This is unlike 
its effect when used as a single intermit-
tent dose where better bronchodilatation 
and bronchoprotection has been noted. 
The concern that regular use of LABA 
would be associated with partial sub 
sensitivity of B2 adenoceptor due to de-
creased lymphocyte B2 receptor den-
sity (tolerance) and cross tolerance to 
SABA requires further clarification given 
the protective effect of corticosteroids. 
Steroids have a facillatory role of B2 
receptor function and numbers and this 
counteract the effect of tolerance and 
limit the decrease in BHR. Tolerance 
is often seen with regular use of short 
acting b2 agonist and may translate into 
reduced bronchoprotection (decreased 
PC20 and increased bronchial hyper re-
activity) that causes an increased clini-
cal vulnerability to unprotected attacks 
while maintaining bronchodilatation and 
normal lung function. 
Tolerability and safety  
LABA are well tolerated without clinically 
important side effects even with long-
term use. There side effect profile is sim-
ilar to that of SABA. They are associated 
with tremors, palpitations, headaches, 
and nausea, and irritability, changes in 
blood glucose and plasma potassium 
levels. In the recent SMART trial from the 
USA, the use of LABAs were assumed 
to be associated with increased asthma 
related mortality in adults. However on 
closer analysis of the data, it was shown 
that this risk was only seen a certain 
subset of Afro-Americans who had a 
genetic predisposition to poor response 
to bronchodilation secondary to a 
higher prevalence of the arg –arg beta 2 
receptor genotype. Also, the phenotype 
of these individuals and their lack of 
adherence to therapy contributed to the 
worse outcome.
Concerns over the use of leukotri-
enes
Although given as an oral medication, 
LTRA have been shown to be safe 
medications. A major concern was the 
increased incidence of Churg Struss 
syndrome following the introduction of 
zafirlukast in the USA. Closer examina-
tion of the data around these episodes 
indicated that the syndrome was more 
likely due to the withdrawal of cortico-
steroids rather than the use of the LTRA. 
Churg Struss syndrome has not been 
seen with use of Montelukast. Another 
adverse effect associated with LTRA 
was the development of hepatitis but 
not was mild and transient.
 
Concerns of the use of theophyllines
Major concern of theophyllines is the er-
ratic absorption and variable drug levels 
with consequence idiosyncratic and 
drug dose dependant adverse effects. 
Cardiac arrthymias and palpitations 
have been observed with use. 
CONCLUSIONS
Advances in our understanding of the 
clinical asthma is likely to change the 
way we consider managing patients 
with the different phenotypes of this 
disease entity, but for the moment, 
given our current knowledge and under-
standing of the condition, combination 
therapy with inhaled corticosteroids 
and long acting beta-2 agonist are the 
first line therapeutic option in adults and 
children with moderate severity asthma. 
In those not adequately controlled on 
this therapy, consideration of the use of 
a leukotriene receptor antagonist should 
be given especially if high combined 
doses of corticosteroids are in use. 
Further research of the use of soluble 
TNF alpha-receptor fusion proteins such 
etanercept in children and adults are 
required to best guide its use.. 
See CPD Questionnaire, page 41
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